Pricing Log in Create free account
Saturday 7 November 2026 Export ZVRA’s income statement to Excel — free account

Zevra Therapeutics, Inc.

ZVRA Healthcare Biotechnology

Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024.

Revenue
+44.9%
EPS
+3,333.0%
Free cash flow
+106.8%
Total debt
+4.07%

Quarter to September 2026, against a year earlier

11.55 1.02 +9.69%
Market cap
$626.6M
P/E
9.0×
Fwd P/E
9.2×
Dividend yield
—
F-score
6/9
Altman Z
0.63
Beneish M
1.46
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 2.52
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — 4 4 — — 1 1 — 2 — 1 —
Insider Ownership 1.51%

Capital & Financial Ratios $m

Size
Market Cap 626.59
Revenue ttm 147.76
Net income ttm 78.02
Free cash flow ttm 87.07
Net debt Q (195.57)
Valuation
P/E 9.00
Forward P/E 9.17
Price / sales 4.64
Forward P/S Powerpack
Price / FCF 7.88
Price / book 2.87
Financial health
Current ratio Q 5.46 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 30.48
Growth
Revenue growth Q +44.86% (above 0%: growing)
Operating income growth Q +179.51% (above 0%: growing)
EPS, this year −8.01% (below 0%: weak)
EPS, next year A −25.82% (below 0%: weak)
Revenue, next year A +43.98% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +2.26%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.0×, against a ten-year median of 6.8×; over the ten years it ranged from 2.3× in 2022 to 18.5× in 2024.
P/S against its own 10 years 15.08%
10-year low 10-year high
P/B against its own 10 years 48.54%
10-year low 10-year high
EV/Sales against its own 10 years 15.39%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 68 69 191 196
Receivables 17 11 23 20
Inventory — 2 2 3
Other — — — —
87 86 223 226
2023 2024 2025 Q'26
Payables 28 25 12 14
ST’ Debt 38 — — —
Other 7 8 14 9
74 34 39 41

Compound Annual Growth %

10y 5y 3y
Sales — 51.62% 118.82%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 27.21%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.14 Actual 0.18

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.04 1.16 Beat by 1.12
Q1 FY26 0.06 0.18 Beat by 0.12
Q2 FY26 0.08 0.25 Beat by 0.17
Q3 FY26 0.14 0.18 Beat by 0.04
Q4 FY26 0.16 — Reports 8 March 2027

EPS $

Mar Jun Sep Dec Year
’26 0.60 0.14 0.31 — —
’25 (0.06) 1.21 (0.01) 0.19 1.35
’24 (0.40) (0.48) (0.69) (0.67) (2.28)
’23 (0.34) (0.08) (0.30) (0.54) (1.30)
’22 (0.05) (0.70) (0.19) 0.17 (0.78)
’21 (2.49) (0.40) (0.06) 0.09 (2.11)
’20 (1.92) 0.16 (0.64) (0.83) (3.21)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 36 40 38 — —
’25 20 26 26 34 106
’24 3 4 4 12 24
’23 3 8 3 13 27
’22 4 1 3 2 10
’21 12 12 2 3 29
’20 2 7 2 2 13
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 6 17 10 — —
’25 (8) (4) 5 6 (2)
’24 (16) (19) (18) (16) (70)
’23 (4) (9) (5) (16) (34)
’22 (4) (4) (7) (4) (19)
’21 (3) 17 (3) (1) 10
’20 (2) 2 (1) (1) (2)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 50 22 10 — —
’25 (8) (4) 5 5 (2)
’24 (16) (19) (18) (16) (70)
’23 (4) (9) (5) (16) (34)
’22 (4) (4) (7) (4) (19)
’21 (3) 17 (3) (1) 10
’20 (2) 2 (1) (1) (2)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 13 13 29 10 27 24 106 148 +42.3% 153 178 225 +28.4%
Gross margin, % 0.00 0.00 0.00 77.06 90.18 92.81 97.82 92.09 68.59 84.52 95.44 +84.5 pt
EBT (17) (43) (57) (25) (13) (9) (27) (46) (90) 87 90 n/m
EBT margin, % 0.00 0.00 0.00 (191.17) (96.28) (29.74) (263.80) (167.69) (381.76) 81.41 60.90 +81.4 pt
Net income (17) (43) (56) (25) (13) (9) (27) (46) (106) 83 78 n/m
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 6.93 3.34 0.96 0.29 0.77 0.51 1.92 2.49 n/m
Earnings (18.08) (47.36) (50.40) (13.28) (3.21) (2.11) (0.78) (1.30) (2.28) 1.40 1.28 n/m
Cash flow (32.63) (36.14) (48.37) (12.81) (0.49) 0.35 (0.54) (0.95) (1.51) (0.03) 0.65 (54.2%)
Capex (0.70) (0.20) (0.02) (0.01) (0.01) 0.00 0.00 (0.01) 0.00 (0.01) 0.81 (40.1%)
Free cash flow (33.34) (36.34) (48.39) (12.82) (0.50) 0.35 (0.55) (0.95) (1.51) (0.04) 1.47 (53.2%)
Book value (20.49) (62.80) (59.40) (40.18) (16.68) 4.27 2.18 1.75 0.86 2.80 4.02 n/m
Shares, m 1 1 1 2 4 30 34 35 46 55 58 +57.8%
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 6.54 9.00 0.9
P/S — — — 0.00 3.36 9.05 15.38 8.82 16.34 4.65 4.64 8.2
P/B — — — 0.00 0.00 2.04 2.08 3.91 9.72 3.20 2.87 3.0
EV/Sales — — — 0.00 8.18 5.18 8.53 7.91 17.51 3.80 3.99 7.3
EV/FCF — — — (3.60) (55.12) 14.40 (4.61) (6.42) (5.91) (203.63) 6.78 (37.8)
Cash, $m
Cash, $m Operating cash flow (30) (33) (54) (24) (2) 10 (19) (34) (70) (2) 39 (27.7%)
Capex (1) 0 0 0 0 0 0 0 — 0 48 (5.5%)
Free cash flow (30) (33) (54) (24) (2) 10 (19) (34) (70) (2) 87 (26.2%)
Balance, $m
Balance, $m Working capital 68 34 12 2 1 111 81 13 52 184 184 +11.7%
Net debt 23 51 60 74 64 (111) (70) (25) (10) (129) (196) n/m
Shareholders’ equity (19) (58) (67) (74) (66) 127 75 62 40 155 239 n/m
Returns, %
Returns, % ROA (23.68) (63.18) (142.59) (131.65) (117.52) (87.27) (21.57) (32.02) (60.21) 33.52 25.69 +57.2 pt
ROIC (529.65) 0.00 0.00 0.00 0.00 29.49 (478.56) (84.03) (183.25) (153.83) 129.48 +375.8 pt
ROE 114.63 113.86 91.01 34.78 18.12 (207.22) (26.48) (67.23) (207.84) 79.85 40.29 (34.8) pt
People
People Employees 32 32 33 22 22 24 36 69 59 61 — +7.4%
Revenue/emp, $m 0.00 0.00 0.00 0.58 0.60 1.19 0.28 0.40 0.40 1.75 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Zevra Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SGMT Sagimet Biosciences Inc. $641.5M — (loss-making) — (loss-making) — n/m −21.95% (below 0%: shrinking) 100.00% 0.00% Compare
WVE WAVE Life Sciences Ltd. $635.1M — (loss-making) — (loss-making) +72.95% (above 0%: growing) n/m −33.94% (below 0%: shrinking) 100.00% (501.95%) Compare
ZVRA Zevra Therapeutics, Inc. $626.6M 9.0× 9.2× +44.86% (above 0%: growing) n/m +106.77% (above 0%: growing) 95.25% 30.67%
FDMT 4D Molecular Therapeutics, Inc. $621.5M — (loss-making) — (loss-making) +25,106.67% (above 0%: growing) n/m −61.28% (below 0%: shrinking) 100.00% (2,037.16%) Compare
DBVT DBV Technologies S.A. $615.8M — (loss-making) — −42.86% (below 0%: shrinking) n/m −64.93% (below 0%: shrinking) 100.00% (4,043.75%) Compare
CADL Candel Therapeutics, Inc. $615.2M — (loss-making) — (loss-making) 0.00% n/m −93.35% (below 0%: shrinking) 0.00% 0.00% Compare
HELP Cybin Inc. $613.0M — (loss-making) — (loss-making) — n/m −25.60% (below 0%: shrinking) 0.00% 0.00% Compare
GERN Geron Corporation $610.4M — (loss-making) — (loss-making) +27.45% (above 0%: growing) n/m +176.13% (above 0%: growing) 89.95% 9.63% Compare
DSGN Design Therapeutics, Inc. $605.2M — (loss-making) — (loss-making) — n/m −7.00% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $615.5M — — +27.45% — −29.77% 94.98% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 20 April 2026

Ownership

Directors and executive officers, together 3.70%
BlackRock, Inc. 6.90%
Woodline Partners LP 5.90%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Zevra Therapeutics, Inc. (ZVRA) Latest News

4 Nov

Impact 3 · · The Motley Fool transcript
Impact 3 · · Moby
Impact 3 · · GuruFocus.com

3 Nov

Impact 3 · · MarketBeat transcript
Impact 3 · · Zacks
Impact 3 · · Associated Press
Impact 3 · · GlobeNewswire

7 Aug

Impact 4 ·

6 Aug

Impact 4 · transcript
Impact 3 · · MarketBeat transcript

5 Aug

Impact 3 ·

3 Aug

Impact 4 ·

24 Jul

Impact 4 · · Stocktwits
Impact 4 · · InvestorsHub
Impact 4 · · Stocktwits
Impact 4 ·

23 Jun

Impact 4 · · GlobeNewswire

9 Jun

Impact 3 · · Simply Wall St.
Impact 3 · · Stocktwits

8 Jun

Impact 4 · · Stocktwits
Impact 4 · · Proactive Investors
Impact 4 · · GlobeNewswire

13 May

Impact 3 · · Simply Wall St.

9 May

Impact 4 · · Simply Wall St.

7 May

Impact 3 · · MarketBeat

6 May

Impact 4 · · Moby
Impact 4 · · The Motley Fool transcript
Impact 4 · · Zacks
Impact 4 · · GlobeNewswire

23 Mar

Impact 3 · · Simply Wall St.
stockrow.com/ZVRA · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com